Bicycle Therapeutics plc Cash and Restricted Cash
Bicycle Therapeutics plc (BCYC) had Cash and Restricted Cash of $510.11 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-07-30
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $510.11M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $560.08M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $628.72M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $648.87M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $510.11M 10-Q · filed 2026-07-30 |
| 2026-03-31 | $560.08M 10-Q · filed 2026-04-30 |
| 2025-12-31 | $628.72M 10-Q · filed 2026-07-30 |
| 2025-09-30 | $648.87M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $722.00M 10-Q · filed 2026-07-30 |
| 2025-03-31 | $793.52M 10-Q · filed 2026-04-30 |
| 2024-12-31 | $880.07M 10-Q · filed 2026-07-30 |
| 2024-09-30 | $891.41M 10-Q · filed 2025-10-30 |
| 2024-06-30 | $961.91M 10-Q · filed 2025-08-08 |
| 2024-03-31 | $457.54M 10-Q · filed 2025-05-01 |
| 2023-12-31 | $526.97M 10-K · filed 2026-03-17 |
| 2023-09-30 | $572.63M 10-Q · filed 2024-10-31 |
| 2023-06-30 | $340.43M 10-Q · filed 2024-08-06 |
| 2023-03-31 | $293.81M 10-Q · filed 2024-05-02 |
| 2022-12-31 | $339.15M 10-K · filed 2026-03-17 |
| 2022-09-30 | $361.47M 10-Q · filed 2023-11-02 |
| 2022-06-30 | $372.77M 10-Q · filed 2023-08-03 |
| 2022-03-31 | $407.37M 10-Q · filed 2023-05-04 |
| 2021-12-31 | $438.68M 10-K · filed 2025-02-25 |
| 2021-09-30 | $259.52M 10-Q · filed 2022-11-03 |
| 2021-06-30 | $198.74M 10-Q · filed 2022-08-04 |
| 2021-03-31 | $195.90M 10-Q · filed 2022-05-05 |
| 2020-12-31 | $135.99M 10-K · filed 2024-02-20 |
| 2020-09-30 | $149.84M 10-Q · filed 2021-11-04 |
| 2020-06-30 | $96.91M 10-Q · filed 2021-08-05 |
| 2020-03-31 | $109.64M 10-Q · filed 2021-05-06 |
| 2019-12-31 | $92.12M 10-K · filed 2023-02-28 |
| 2019-09-30 | $95.95M 10-Q · filed 2020-11-05 |
| 2019-06-30 | $108.54M 10-Q · filed 2020-08-05 |
| 2019-03-31 | $59.36M 10-Q · filed 2020-05-07 |
| 2018-12-31 | $63.38M 10-K · filed 2022-03-01 |
| 2018-09-30 | $47.92M 10-Q · filed 2019-11-07 |
| 2018-06-30 | $53.40M 10-Q · filed 2019-08-08 |
| 2017-12-31 | $67.66M 10-K · filed 2021-03-11 |
| 2016-12-31 | $9.40M 10-K · filed 2020-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B |